ADPT President and COO Julie Rubinstein Sells $305K of Stock

Adaptive Biotechnologies Corporation President and COO Julie Rubinstein sold 11,881 shares of the company on October 14, 2026. The transaction was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission.

Inside Julie Rubinstein's Adaptive Biotechnologies Trade

Julie Rubinstein executed the sale at an average price of $25.68, bringing the total value of the transaction to $305,072.0. The trade was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Rubinstein holds 377,802.0 shares of the company, cutting her stake by about 3.05%. This follows three similar sales executed earlier in October as part of her planned trading schedule.

Other Institutional Activity in Adaptive Biotechnologies Corporation

Other large funds have adjusted their stakes in the diagnostics firm recently. Viking Global Investors, L.P. maintained its position, ending with 29,993,708.0 shares worth about $720,448,879.0. Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859.0 shares worth about $111,113,135.0. Meanwhile, Westfield Capital Management Co LP trimmed its stake by 1,168,845 shares, ending with 4,267,645.0 shares worth about $102,508,834.0.

Adaptive Biotechnologies Corporation Stock Down 5.4%

The stock recently traded around $24.19 as of October 17, 2026. On the day of the insider trade, Adaptive Biotechnologies shares closed at $25.62.

Recent Earnings

Adaptive Biotechnologies posted trailing twelve-month revenue of $308,080,992.0 with an earnings per share of -$0.41. The firm reported a net margin of -20.7% and a return on equity of -38.8%. The company is scheduled to report its next earnings on November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Insiders have been active in the company's shares over recent months. Sharon Benzeno bought 103,295.0 shares on June 29, 2026, at an average price of $7.28. Julie Rubinstein executed multiple planned sales earlier in October, including 11,881.0 shares on October 9, October 12, and October 13.

Analysts Set New Price Targets

Several Wall Street firms updated their views on the stock ahead of the filing. BTIG maintained a Buy rating on September 22, 2026, raising its target to $34.0. Goldman Sachs initiated coverage with a Buy rating and a $35.0 target on September 29, 2026. Guggenheim maintained a Buy rating on October 1, 2026, lifting its target to $32.0. TD Cowen maintained a Buy rating with a $32.0 target on October 13, 2026, while Morgan Stanley maintained an Equal-Weight rating with a $27.0 target on the same day. Overall, the stock holds a strong buy consensus with a mean target price of $29.81.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a commercial-stage healthcare company based in Seattle, Washington. It develops an immune medicine platform that combines proprietary chemistry, computational biology, and machine learning to decode the human adaptive immune system for diagnostic and therapeutic applications.

Bottom Line

Investors will look toward the upcoming earnings report on November 4, 2026, for further updates on financial performance. Monitoring subsequent Form 4 filings will provide additional insight into executive stock transactions.